Recombinant Human ANGPTL8 protein
Cat.No. : | ANGPTL8-190H |
Product Overview : | Recombinant human Betatrophin cDNA ( 177aa ) was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
Source : | E. coli |
Species : | Human |
Form : | 1.0 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, Sucrose and DTT. |
AA Sequence : | MTLHRNEYGIASILDSYQCTAEISL ADLATIFFAQFVQEATYKEVSKMVK DALTAIEKPTGDEQSSGCLENQLPA FLEELCHEKEILEKYGHSDCCSQSE EGRHNCFLAHKKPTPASIPLFQVPE PVTSCEAYEEDRETFMNKFIYEIAR RHPFLYAPTILLWAARYDKIIPSCC KAENAVECFQTKAATVTKELRESSG GSHHHHHHGSENLYFQGAPMGGPEL AQHEELTLLFHGTLQLGQALNGVYR TTEGRLTKARNSLGLYGRTIELLGQ EVSRGRDAAQELRASLLETQMEEDI LQLQAEATAEVLGEVAQAQKVLRDS VQRLEVQLRSAWLGPAYREFEVLKA HADKQSHILWALTGHVQRQRREMVA QQHRLRQIQERLHTAALPA |
Purity : | >90% by SDS-PAGE |
Applications : | 1. May be used for in vitro human Betatrophin signaling pathway regulation study for human pancreatic beta cell differentiation.2. As antigen for specific antibody production. |
Storage : | Keep at -80 centigrade for long term storage. Product is stable at 4 centigrade for at least 7 days. |
Publication : |
Recombinant betatrophin (Angptl‑8/lipasin) ameliorates streptozotocin‑induced hyperglycemia and β‑cell destruction in neonatal rats (2019)
|
Gene Name : | ANGPTL8 angiopoietin like 8 [ Homo sapiens ] |
Official Symbol : | ANGPTL8 |
Synonyms : | RIFL; TD26; PRO1185; PVPA599; C19orf80; angiopoietin-like 8; betatrophin variant 1; betatrophin variant 2; hepatocellular carcinoma-associated gene TD26; hepatocellular carcinoma-associated protein TD26; lipasin; refeeding-induced fat and liver protein |
Gene ID : | 55908 |
mRNA Refseq : | NM_018687 |
Protein Refseq : | NP_061157 |
MIM : | 616223 |
UniProt ID : | Q6UXH0 |
Chromosome Location : | 19p13.2 |
Function : | hormone activity; hormone activity; protein binding |
Products Types
◆ Recombinant Protein | ||
ANGPTL8-1699M | Recombinant Mouse ANGPTL8 Protein (16-198 aa), His-tagged | +Inquiry |
ANGPTL8-2078H | Recombinant Human ANGPTL8 Protein, His-tagged | +Inquiry |
Angptl8-315M | Recombinant Mouse Angptl8 Protein, His-tagged | +Inquiry |
ANGPTL8-01H | Active Recombinant Human ANGPTL8 Protein, His-tagged | +Inquiry |
Angptl8-5916M | Recombinant Mouse Angptl8 protein, His-tagged | +Inquiry |
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (16)
Ask a questionThe potential of ANGPTL8 as a therapeutic target for diabetes is still being explored. Given its involvement in lipid and glucose metabolism, modulating ANGPTL8 levels or activity could have implications for diabetes treatment. However, more research is needed to better understand the exact mechanisms and potential side effects associated with targeting ANGPTL8 before it can be considered a viable therapeutic option.
At present, there are no drugs specifically targeting ANGPTL8 that have been approved for clinical use. However, researchers are actively investigating the therapeutic potential of modulating ANGPTL8 levels or activity for the management of metabolic disorders. This includes exploring small molecule inhibitors, monoclonal antibodies, and other strategies to target ANGPTL8 and its related pathways.
ANGPTL8 has been reported to have effects on glucose metabolism. Studies have shown that ANGPTL8 can increase glucose uptake in muscle cells by enhancing insulin sensitivity. ANGPTL8 has also been associated with improved insulin secretion from pancreatic beta-cells. These findings suggest that ANGPTL8 may be involved in regulating glucose metabolism and maintaining glucose homeostasis.
Research suggests that ANGPTL8 may have a role in promoting the proliferation of pancreatic beta-cells. Beta-cells are responsible for producing and secreting insulin in the pancreas. ANGPTL8 has been shown to increase beta-cell proliferation in certain experimental models. This suggests that it may have a beneficial effect on insulin production and potentially be involved in the regulation of glucose metabolism.
Research has suggested a potential link between ANGPTL8 and type 2 diabetes. ANGPTL8 levels have been found to be elevated in individuals with obesity and insulin resistance, which are risk factors for type 2 diabetes. However, further studies are needed to fully understand the impact of ANGPTL8 on the development and progression of this disease.
There is ongoing interest in exploring ANGPTL8 as a biomarker for metabolic disorders such as obesity and type 2 diabetes. Elevated levels of ANGPTL8 have been observed in individuals with these conditions. However, more research is required to determine its diagnostic and prognostic utility and to establish reliable cutoff values for clinical use.
Genetic variations and mutations in the ANGPTL8 gene have been investigated for their potential association with various diseases. Some studies have identified specific ANGPTL8 gene variants that may be linked to obesity, insulin resistance, and type 2 diabetes susceptibility. However, further research is required to confirm these associations and to determine the functional impact of genetic variations in ANGPTL8.
There is emerging evidence suggesting a potential link between ANGPTL8 and cardiovascular health. Studies have shown associations between ANGPTL8 levels and markers of cardiovascular risk, such as dyslipidemia and atherosclerosis. However, more research is needed to establish the precise mechanisms through which ANGPTL8 may affect cardiovascular health and whether it has a causal role in the development or progression of cardiovascular diseases.
The regulation of ANGPTL8 expression is complex and involves multiple factors. It can be influenced by various hormones and metabolic signals. For example, insulin, glucagon, and free fatty acids have been shown to affect ANGPTL8 expression. Additionally, certain transcription factors and signaling pathways are involved in the regulation of ANGPTL8 gene expression.
Yes, ANGPTL8 is believed to play a role in energy homeostasis, which refers to the balance between energy intake and expenditure in the body. ANGPTL8 is released by adipose tissue and the liver in response to insulin signaling, and it can regulate the breakdown and storage of lipids. By inhibiting lipoprotein lipase (LPL), ANGPTL8 can influence the availability of fatty acids for energy metabolism or storage, thereby contributing to energy balance.
Yes, ANGPTL8 has been linked to insulin resistance, which is a condition characterized by decreased sensitivity to the effects of insulin. Insulin resistance is often observed in obesity and type 2 diabetes. Studies have shown that ANGPTL8 levels are elevated in individuals with insulin resistance, and its overexpression in mice can induce insulin resistance. However, the precise mechanisms underlying this association require further investigation.
The potential therapeutic implications of targeting ANGPTL8 are still being explored. As ANGPTL8 is involved in metabolic processes and its dysregulation has been associated with conditions such as obesity and type 2 diabetes, modulating its levels or activity could potentially have therapeutic benefits. Targeting ANGPTL8 could be an avenue for developing treatments for metabolic disorders, but more research is needed to determine the safety and efficacy of such interventions.
As ANGPTL8 modulation is still in the early stages of research, the potential side effects and risks are not well-defined. It is essential to thoroughly investigate the effects of targeting ANGPTL8 before any therapeutic interventions can be considered. Future studies will help in evaluating the safety and potential adverse effects of ANGPTL8 modulation approaches.
In addition to its potential involvement in metabolic disorders, ANGPTL8 may have other physiological functions and roles in disease. Some studies suggest that it could influence lipid metabolism, liver function, and cardiovascular health. ANGPTL8 has also been implicated in certain cancers, but more research is needed to fully understand its contribution in these contexts.
Yes, ANGPTL8 levels in the bloodstream can be measured through laboratory tests. Various techniques, including enzyme-linked immunosorbent assay (ELISA), have been used to quantify ANGPTL8 levels in biological samples such as plasma or serum. However, it is important to note that standardized assays and reference ranges are still being established.
ANGPTL8 has been implicated in regulating lipid metabolism. It functions as an endocrine factor that can inhibit lipoprotein lipase (LPL), an enzyme responsible for breaking down triglycerides in the bloodstream. By inhibiting LPL, ANGPTL8 can increase the levels of triglycerides in the blood, providing a potential mechanism for its role in lipid metabolism.
Customer Reviews (4)
Write a reviewAs a researcher utilizing the Angptl8 protein, I am fortunate to benefit from its numerous advantages in trials.
the Angptl8 protein exhibits remarkable stability, enabling it to maintain its structural integrity and functionality throughout the experimental process.
the Angptl8 protein offers exceptional quality and purity, which is crucial for ensuring reliable and reproducible experimental outcomes.
the manufacturer of the Angptl8 protein plays a vital role in supporting my research endeavors.
Ask a Question for All ANGPTL8 Products
Required fields are marked with *
My Review for All ANGPTL8 Products
Required fields are marked with *
Inquiry Basket